Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07349498 (CORE-HCT) für Hämatopoetische Stammzelltransplantation, Transplantationskomplikation, Kardiovaskuläre Ereignisse ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT) 10.000 Beobachtend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07349498 (CORE-HCT) ist eine beobachtungsstudie zur Untersuchung von Hämatopoetische Stammzelltransplantation, Transplantationskomplikation, Kardiovaskuläre Ereignisse und hat den Status offene rekrutierung. Die Studie startete am 1. Januar 2026 und soll 10.000 Teilnehmer aufnehmen. Durchgeführt von Peking University People's Hospital ist der Abschluss für 31. Dezember 2036 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 16. Januar 2026 aktualisiert.
Kurzbeschreibung
This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.
Offizieller Titel
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation (CORE-HCT): A Prospective Multicenter Observational Study
Erkrankungen
Hämatopoetische StammzelltransplantationTransplantationskomplikationKardiovaskuläre EreignisseWeitere Studien-IDs
- CORE-HCT
- 2025-z232
NCT-Nummer
Studienbeginn (tatsächlich)
2026-01-01
Zuletzt aktualisiert
2026-01-16
Studienende (vorauss.)
2036-12-31
Geplante Rekrutierung
10.000
Studientyp
Beobachtungsstudie
Status
Offene Rekrutierung
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Patients undergoing hematopoietic stem cell transplantation Patients who undergo allogeneic hematopoietic stem cell transplantation at participating medical center. | Nicht zutreffend |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Major adverse cardiovascular events (MACE) | Major adverse cardiovascular events (MACE) after hematopoietic stem cell transplantation. | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Cardiovascular events | Cardiovascular events after hematopoietic stem cell transplantation, such as cardiovascular death, ischemic heart disease, coronary artery disease, stroke, heart failure, arrhythmia cardiomyopathy, myocarditis, endocarditis, valvular heart disease, and pericardial disease. | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. |
Overall survival | Overall survival after hematopoietic stem cell transplantation. | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. |
Event-free survival | Events were defined as the occurrence of any of the following after allo-HSCT: grade III-IV acute graft-versus-host disease (GVHD), chronic GVHD requiring systemic immunosuppression, relapse or progression of the hematologic disease, or death from any cause during follow-up. | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. |
Complications of hematopoietic stem cell transplantation | Complications arising from hematopoietic stem cell transplantation range from early issues such as regimen toxicity and acute GVHD to late effects including chronic GVHD, organ dysfunction, and secondary malignancies. | At 30 days, 100 days, 3 months, 6 months, 1 years, 3 years, 5 years post hematopoietic stem cell transplantation. |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Zugelassene Geschlechter
Alle
- Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.
- Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
- Patient request to withdraw from the study.
Peking University People's HospitalVerantwortliche Partei
Xiao Hui Zhang, Hauptprüfer, MD, Peking University People's Hospital
Zentrale Studienkontakte
Kontakt: Xiao Hui Zhang, 861088324577, [email protected]
16 Studienstandorte in 1 Ländern
Beijing Municipality
Chinese PLA General Hospital, Beijing, Beijing Municipality, China
Dai Hong Liu, Kontakt
Offene Rekrutierung
Peking University First Hospital, Beijing, Beijing Municipality, China
Yu Jun Dong, Kontakt
Offene Rekrutierung
Peking University People's Hospital, Beijing, Beijing Municipality, China
Xiao Hui Zhang, Kontakt, 861088324577, [email protected]
Offene Rekrutierung
Peking University Third Hospital, Beijing, Beijing Municipality, China
Hong Mei Jing, Kontakt
Offene Rekrutierung
Chongqing Municipality
Xinqiao hospital of the third military medical university, Chongqing, Chongqing Municipality, China
Xi Zhang, Kontakt
Offene Rekrutierung
Guangdong
Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Yang Liang, Kontakt
Offene Rekrutierung
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Hong Yu Zhang, Kontakt
Offene Rekrutierung
Heilongjiang
First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Sheng Jin Fan, Kontakt
Offene Rekrutierung
Henan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Zhong Xing Jiang, Kontakt
Offene Rekrutierung
Hubei
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Yi Cheng Zhang, Kontakt
Offene Rekrutierung
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Ling Hui Xia, Kontakt
Offene Rekrutierung
Shaanxi
First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China
Peng Cheng He, Kontakt
Offene Rekrutierung
Sichuan
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Xiao Bing Huang, Kontakt
Offene Rekrutierung
Tianjin Municipality
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), Tianjin, Tianjin Municipality, China
Er Lie Jiang, Kontakt
Offene Rekrutierung
Xinjiang
First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
Ming Jiang, Kontakt
Offene Rekrutierung
Zhejiang
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Yi Luo, Kontakt
Offene Rekrutierung